Total Funding
44
Total FundingSeries A raised
Growth Score
pts
Heat Score
-12 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
2292598
HepaVec AG is a privately held biotechnology company.
About the Company
HepaVec AG is a privately held biotechnology company, focused on the development of novel therapeutic products for addressing malignant and genetic liver diseases, and on cell engineering of hepatocytes (liver cells). HepaVec has developed new gene transfer systems (vectors), derivatives of baculovirus and an ovine (sheep) adenovirus (OAV), which
enable efficient and specific delivery of therapeutic genes into human liver cells. In the combat against liver cancer, HepaVec's lead product regulates the cell cycle to selectively drive cancer cells to programmed cell death (apoptosis) and is scheduled to enter a Phase I/II clinical trial in 2000.
